Advances in the pharmacological treatment of rare multiple sclerosis variants

30 April 2021
rare_diseases_credit_depositphotos

By Dr Nicola Davies

Rare forms of multiple sclerosis (MS) exhibit certain atypical imaging characteristics that are absent in typical MS, although the clinical features of these variants are similar to typical MS. Although the rarity of these diseases restricts the research and development of disease-specific therapies, some progress has been made. In this exclusive article, Dr Davies investigates this progress.

Tumefactive MS

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical